Kura Oncology

News

Kura Oncology and Kyowa Kirin logos with Komzifti pill bottle

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

News

Kura hit as FDA slaps partial hold on leukaemia trial

Share in Kura Oncology have come under pressure after a patient death in a clinical trial of the US biotech's acute myeloid leukaemia (AML) therapy KO-539, provisionally attributed to a sid

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura files $100m offer after menin inhibitor results in AML...

Kura hit as FDA slaps partial hold on leukaemia trial

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks